Background: As cancer progresses, methylation patterns change to promote the tumorigenic phenotype. However, the stability of methylation markers over time and the extent that biopsy samples are representative of larger tumor specimens are unknown.
Introduction
There is a growing body of literature showing associations between molecular markers and head and neck cancer. These markers are being developed as potential clinical tools to direct treatment, to identify low-risk patients that may benefit from less harsh treatments and to predict prognosis. The use of epigenetic markers is a promising tool in this regard. These markers do not change the sequence of DNA, may be reversible and are indicative of tumor biology (1) . Specifically, variation in DNA methylation is one of the hallmark processes of cancer and potentially, these markers might be used as therapeutic targets alone, or to select patients for more effective therapy. For example, gene promoter hypermethylation of the DNA repair gene MGMT is a prognostic marker for glioma patients and is currently being evaluated as marker for patient selection for a treatment option in conjunction with carmustine and temozolomide in clinical trials (1, 2) . TMethylation of the mismatch repair gene, hMLH1, was found to significantly increase upon relapse of epithelial ovarian cancer patients and was associated with poor survival (3) . be associated with resistance to cisplatin in ovarian cancer cell lines (3) . These cells were re-sensitized using a demethylating agent, offering potential value of these findings in a clinical setting (4, 5) .
Hypermethylation of a DNA helicase gene involved in DNA replication, recombination and DNA repair, WRN, increases sensitivity of colorectal tumors to topoisomerase inhibitors.
Combined therapy with DNA damaging agents showed significantly better prognosis in patients with hypermethylated WRN than in patients with unmethylated WRN (4) . Such markers offer high translatability into the clinical setting and can allow for personalized therapy with high efficacy depending upon the methylation profile of a patient's tumor.
An inherent limitation of incorporating methylation markers clinically is that the persistence of methylation in a tumor is unknown. As cancer progresses, methylation patterns can change to promote the tumor phenotype (5, 6) . Further, methylation of specific genes could differ significantly depending on timing and site of tumor sampling. However, methylation markers that are known to persist over time can may potentially be used to direct treatment. Further, methylation of specific genes could differ significantly depending on timing and site of tumor sampling. Whether biopsy specimens would be
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Methylation Stability over Time 4 representative of samples obtained at surgical resection is particularly important in head and neck cancer where non-surgical primary treatment is becoming more common. This report addresses this important limitation and provides evidence that tumor biopsy specimens can be used to promote the development of epigenetically based treatments for cancer in a clinical setting. Here, we measure the methylation of four genes across time:
CCNA1 (cyclin A1), NDN (necdin), DCC (deleted in colorectal carcinoma) and CD1a (cluster of differentiation 1a). These specific genes were chosen based on their potential for clinical relevance and our previous work that identified methylation of these genes to be prognostic indicators in a large cohort of head and neck squamous cell carcinoma patients (7) .A discovery-based study previously published by our group, was designed to identify novel prognostic epigenetic biomarkers for patients with HNSCC (7, 8) . CCNA1 (cyclin A1) was found to be differentially methylated by HPV status (7) . NDN (necdin) and CD1a (cluster of differentiation 1a) were also differentially methylated in this discovery analysis, however they were not significant, potentially due to small sample size. NDN is an imprinted gene previously implicated in epithelial ovarian, bladder, breast, colorectal, and urothelial cancers, as well as premalignant lesions such as vulval intraepithelial neoplasia and Barrett's oesophagus, although has not been studied in the context of HNSCC (7) (8) (9) (10) (11) (12) (13) (14) . CD1A was the first immune gene found to be differentially methylated in the discovery analysis.
CD1A methylation has not been previously studied in HNSCC, however significant hypermethylation of CD1B, CD1C, CD1D and CD1E has been found in HPV (+) HNSCC tumors compared to HPV(-) tumors (15) . DCC (deleted in colorectal carcinoma), GADD45 (growth arrest and DNA damage 45) and p16 (cyclin-dependent kinase inhibitor) were previously found to be hypermethylated in HNSCC and were chosen for their role as tumor suppressors and potential involvement with HPV (16) (17) (18) (19) (20) . Previous literature on the importance of these genes in HNSCC highlights their potential clinical relevance. However, validation of their methylation stability across time is critical in determining the clinical utility of these epigenetic biomarkers. (21) . Eligible subjects were biopsied pretreatment and diagnosed with head and neck squamous cell carcinoma at an outside hospital (OSH) before referral to the University of Michigan (UM) for treatment. Upon presentation at UM, patients may be rebiopsied and staged during treatment planning. Ninety-eight subjects that signed a written, informed consent, had both a formalin-fixed paraffin-embedded (FFPE) biopsy specimen from an OSH and a surgical resection (n=70) or biopsy (n=28) specimen from UM at a second time point available for microdissection and methylation analysis. according to the manufacturer's recommended protocol. HPV status was determined by an ultrasensitive method using real-time competitive polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization mass spectroscopy HPV type was distinguished by mass when analyzed on the MALDI-TOF mass spectrometer as described and validated previously, due to its low DNA input requirement and rapid identification of HPV types, with high sensitivity and specificity (18, (22) (23) (24) (25) .
Materials and Methods
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Methylation Stability over Time 6 Methylation Analysis. Methylation assays for promoter regions of DCC, CD1A, and NDN, were designed using PyroMark Assay Design 2.0 software and conducted via pyrosequencing across 5 , 2, and 3 CpG sites, respectively (Qiagen, Valencia, CA, USA). The promoter region of CCNA1 was sequenced across 4 CpG sites using the Sequenom EpiTyper, a MALDI-TOF mass spectrometry based platform, due to its CpG-dense promoter region and subsequent difficulty in using pyrosequencing methodology. These assays were designed to cover CpG sites at or near the CpG sites found in our previous study to be prognostic indicators of head and neck squamous cell carcinoma. All primer sets and PCR conditions are listed in Table 1S . Bisulfite singleplex PCR amplification was performed using FastStart Taq Table 2S . Site-specific and mean methylation from matched tissue specimens across time for CCNA1, DCC, and CD1A were compared using a non-parametric Wilcoxon-signed rank test due to skewed distributions. Methylation values for NDN were compared using a paired t-test due to its Gaussian distribution. Pearson (NDN) and Spearman (CCNA1, DCC, and CD1A) correlation coefficients and 95% confidence intervals (CIs) were calculated for methylation across both time points. The difference in methylation between time points was calculated for each gene and the differences and their absolute values were tested for correlation with the number of days between specimens. Correlation coefficients were also calculated subsetting by HPV status, smoking status, days between time points and specimen type of second sample. Differences in the amount of change in methylation values across subsets were tested using Wald tests from linear regression models and a correction
Methylation Stability over Time 7 for false discovery was applied to the p-values to adjust for multiple comparisons of the various subgroup tests using q-values described by Storey et al. (26) Multivariable analyses was conducted separately for each gene using a linear model to measure the association of days between sample collection and methylation differences, adjusting for HPV status, age, site, stage and comorbidity status. Comorbidity data were abstracted from the medical record and graded by severity (none, mild, moderate, severe) using the Adult Comorbidity Evaluation of 27 conditions organized by 12 systems (ACE-27).
Results
The study population consisted of 98 paired samples with the median time between first and second tumor tissue specimens at 44 days (range: 8-156 days). Approximately 74% of the population was male. Tumor sites were primarily distributed across larynx, oral cavity and oropharynx (16%, 53%, and 29%, respectively) with 2% in the hypopharynx.
Most patients were HPV-negative (69%). Only 16% were nonsmokers, while 46% were current smokers, or having quit within the past 12 months, and 38% were former smokers (quit more than one year ago). Mean age was 60 years (SD=13 years). All genes showed a wide range of methylation levels across samples, as expected for a labileof epigenetic methylation markers. There were no significant differences in overall methylation within There were no differences in methylation at each CpG site across time (Figure 2a, Figure   2b ). There were no correlations between the differences in methylation between the two As temporal changes in methylation levels may be associated with patient and tumor characteristics, correlations were also calculated separately by HPV status, smoking parameters, and whether the second specimen was from a biopsy or surgery resection; correlations were also calculated by the length of time between specimen sampling ( Table   2) respectively). To determine correlations accounting for intensity and duration of smoking, pack-years were also considered, using 20 pack-years as a cutoff (27) . Patients with less than 20 pack-years and with 20 pack-years or greater showed the most stable methylation at CD1A (rho (95% CI) =0.78 (0.57, 0.89) and 0.73 (0.57, 0.84) respectively). None of the
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Probability of stable methylation across time
It is difficult to define methylation cutoffs that are biologically relevant. To compare consistency across time, we determined the proportion of specimens that fell within 10% and 20% of methylation at the first time point. Methylation was most consistent across time for CCNA1 and NDN. Approximately 91% and 96% of patients, respectively, had methylation levels of these markers at the second time point within 20% of methylation at the first time point. CD1A and DCC methylation at the second time point was within 20% of methylation at the first time point for 85% and 79% of the patient population, respectively. This consistency persisted when restricting methylation change to 10%. Approximately 66% and 68% of patients had methylation of CCNA1 and NDN at the second time point within 10% of methylation at the first time point, respectively. The probability of CD1A and DCC methylation at the second time point staying within 10% of the first time point was 60% and 53%, respectively.
Discussion
These findings in head and neck cancer patients demonstrate the stability of DNA methylation changes in tumor specimens from the time of biopsy to time of surgical treatment or second biopsy ranging from 8 to 156 elapsed days. To date, this is the first study to examine changes in methylation of specific genes across time and from different tumor samples within the same patients.
Correlations across time and by patient characteristic were positive and statistically significant, although the strength of correlations differed slightly based on patient characteristics, potentially due to underlying biological mechanisms associated with these genes. For example, we found that methylation of our genes was more strongly correlated across time in HPV-tumors, likely due to that fact that HPV+ tumors tend to have more DNA methylation events in genic regions (8) . The strength of correlations was higher in
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A limitation of this study is the variability of methylation within each gene. Since the differences observed between paired specimens were uncorrelated with length of time separating the specimens, they are instead likely due to heterogeneity within the tumors, measurement variability in the assay itself, measurements made across mixed cell populations, averages taken across several CpG sites in promoter regions or intraindividual variability in methylation across time. It is important to note that although our biopsies came from a separate institution, the management of the biopsy material is fairly standardized across hospitals. The sample is placed in formalin immediately upon excision and eventually embedded in paraffin. There are many factors that may potentially affect methylation, the most significant being sampling error due to samples being taken from differing locations in the tumor (i.e. periphery for the biopsy and perhaps more central location for the resection). However, because minimal differences were noted in methylation between these two time points and locations, it is unlikely that differing institutions would be a significant variable. NeverthelessIn addition, our findings showed no significant differences in paired distributions, relatively strong correlation coefficients as high as 0.84 and high probabilities of stable methylation within patients across time.
These findings support the conclusion that when targeting epigenetic changes, alterations in gene methylation after initial biopsy likely reflects biologic changes rather than sampling errors. Additionally, these are issues that are likely to impact any clinical measurement, and thus these results represent a realistic assessment of the persistence of methylation levels.
The amount of methylation change needed to instigate a biological effect is currently unknown. Therefore, it is important that methylation levels remain relatively consistent across time when considered in a clinical setting. Here, we show high probabilities of CCNA1 and NDN methylation to be within 10% and 20% of the first measurement.
However, CD1A and DCC methylation had lower probabilities indicating that in the tumor microenvironment, some genes are stably methylated while others are not, presumably to promote the tumorigenic phenotype.
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Although stability of methylation of other specific genes could differ, our current findings are significant since these genes have been shown to be important in HNSCC (7, 8) .
We report CCNA1 and DCC methylation levels similar to previous studies (28) (29) (30) . CD1A and NDN methylation has not been previously reported. The results of this study provide evidence for the stability over time of specific gene methylation measured in biopsy samples and supports the use of biopsy results as representative of the entire tumor, and as a potential prognostic indicator that could aid in defining personalized treatment. 
